Some experts fear FDA’s plasma decision will hinder research; UMass doctor touts benefits - The Boston Globe

Some experts fear FDA’s plasma decision will hinder research; UMass doctor touts benefits - The Boston Globe: The FDA’s decision this week to allow convalescent plasma as a treatment for COVID-19 will make it harder to conduct rigorous studies of its effectiveness, because patients will demand the therapy rather than agreeing to studies in which they might get a placebo, experts said Monday.